Mucosolvan (Ambroxol Hydrochloride)

Mucosolvan is a mucolytic medication used in disorders of the respiratory tract where thick mucus impairs ventilation.

• Acute bronchitis: improves mucus clearance and reduces cough frequency.
• Chronic bronchitis: facilitates expectoration and lowers sputum viscosity.
• COPD exacerbations: aids removal of secretions and eases breathing.
• Respiratory tract infections with excessive mucus: enhances mucociliary transport and patient comfort.

• Ambroxol Hydrochloride stimulates serous mucus production and reduces the viscosity of bronchial secretions by acting on the surfactant system. It also exerts local anesthetic and anti‑inflammatory actions on airway epithelium, thereby promoting more efficient clearance of mucus and improving respiratory function.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Vomiting: occasional emesis after administration.
• Taste disturbances: altered taste perception.
• Injection site pain: mild discomfort at the IV site.
• Headache: transient cranial discomfort.
• Mild rash: limited skin irritation.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• Severe skin reactions: such as Stevens‑Johnson syndrome.
• Bronchospasm: sudden airway constriction.
• Hepatic dysfunction: abnormal liver enzyme elevations.
• Neutropenia: reduced white blood cell count.
• Severe hypotension: marked drop in blood pressure.

Before initiating therapy, consider the following precautions:

• Assess renal function: adjust use in patients with severe impairment.
• Monitor for hypersensitivity: discontinue if allergic reactions occur.
• Use with caution in asthma: may provoke bronchospasm.
• Avoid in known ambroxol hypersensitivity: contraindicated.
• Evaluate liver function: rare hepatic effects may require monitoring.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ambroxol may interact with several medicines; awareness of these interactions helps ensure safe use.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase ambroxol plasma levels.
• Concurrent use with other mucolytics (e.g., N‑acetylcysteine): risk of excessive mucus thinning.
• Combination with beta‑blockers in asthmatic patients: may blunt bronchodilation.

Moderate Interactions (Monitor Closely)

• Anticoagulants (warfarin): potential enhancement of anticoagulant effect.
• NSAIDs: may increase gastrointestinal irritation.
• Theophylline: monitor for additive respiratory effects.